Travere Therapeutics (TVTX) CLO exercises options and sells 10K shares

Rhea-AI Filing Summary

Travere Therapeutics’ Chief Legal Officer Elizabeth E. Reed exercised employee stock options to acquire 10,000 shares of common stock at an exercise price of $19.08 per share, then sold 10,000 shares at a weighted average price of $28.0861 per share.

The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025, tied to a stock option grant expiring on January 4, 2027. Following these transactions, Reed holds 105,211 shares of Travere Therapeutics common stock directly.

Insider Trade Summary 10b5-1

Exercise and Sale: 10,000 shares ($90K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider REED ELIZABETH E

Role Chief Legal Officer and GC

Sold 10,000 shs ($281K)

Approx. gross sale proceeds $281K

Approx. exercise cost $191K

Approx. pre-tax spread $90K

Type	Security	Shares	Price	Value
Exercise	Employee stock option (right to buy)	10,000	$0.00	$0.00
Exercise	Common Stock	10,000	$19.08	$191K
Sale	Common Stock	10,000	$28.0861	$281K

Holdings After Transaction: Employee stock option (right to buy) — 10,000 shares (Direct); Common Stock — 105,211 shares (Direct)

Footnotes (3)

1. F1. This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 4, 2017 with an expiration date of January 4, 2027.
2. F2. The weighted average sale price for the transaction reported was $28.0861, and the range of prices were between $27.66 and $28.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
3. F3. The stock option is fully vested and exercisable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/18/2026 - 04:05 PM Learn about SEC filing dates

FAQ

What insider transactions did Travere Therapeutics (TVTX) report for Elizabeth E. Reed?

Travere Therapeutics reported that Chief Legal Officer Elizabeth E. Reed exercised options for 10,000 shares at $19.08 and sold 10,000 shares at a weighted average of $28.0861. After these transactions, she directly holds 105,211 shares of common stock.

Was the Travere Therapeutics (TVTX) insider share sale made under a Rule 10b5-1 plan?

Yes. The sale was executed under a written trading plan adopted on June 16, 2025 that meets Rule 10b5-1(c) requirements. Such pre-arranged plans are designed to enable systematic selling regardless of near-term market conditions or undisclosed company information.

At what prices did Travere Therapeutics’ Chief Legal Officer transact shares?

Elizabeth E. Reed exercised stock options at an exercise price of $19.08 per share and sold 10,000 shares at a weighted average sale price of $28.0861. The sale price range was between $27.66 and $28.40, according to the disclosure.

How many Travere Therapeutics (TVTX) shares does Elizabeth E. Reed own after the reported Form 4?

Following the reported option exercise and share sale, Elizabeth E. Reed directly owns 105,211 shares of Travere Therapeutics common stock. This figure reflects her position after acquiring 10,000 shares via option exercise and selling 10,000 shares on the same date.

What type of derivative security did Travere Therapeutics’ insider exercise?

The insider exercised an employee stock option covering 10,000 shares of Travere Therapeutics common stock with an exercise price of $19.08 per share. The option was fully vested and exercisable and carried an expiration date of January 4, 2027 at the time of exercise.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

REED ELIZABETH E

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DR., SUITE 300

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer and GC

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/16/2026		M		10,000	A	$19.08	115,211	D
Common Stock	03/16/2026		S(1)		10,000	D	$28.0861(2)	105,211	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$19.08	03/16/2026		M			10,000	(3)	01/04/2027	Common Stock	10,000	$0	10,000	D

Explanation of Responses:

1. This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 4, 2017 with an expiration date of January 4, 2027.

2. The weighted average sale price for the transaction reported was $28.0861, and the range of prices were between $27.66 and $28.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

3. The stock option is fully vested and exercisable.

	/s/ Elizabeth E. Reed	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)